VerityRankVerityRank
Back to Rankings
Roquette Frères SA
Brand VerifiedFrance

Roquette Frères SA

Roquette

Roquette is a global leader in plant-based pharmaceutical excipients and specialty carbohydrates, headquartered in Lestrem, France. Founded in 1933, the company generates annual revenue of €4.9 billion and operates 40+ manufacturing sites across the globe, employing 11,000+ people. Roquette's 2025 acquisition of IFF Pharma Solutions transformed it into the world's largest player in oral solid dosage form excipients.

Strengths: Unmatched scale in polyols and starch-derived excipients following the IFF Pharma Solutions acquisition; vertically integrated supply chain from agricultural raw materials to finished pharma-grade excipients; 20+ global R&D centers driving continuous innovation in co-processed excipients and plant-based alternatives; dominant market share in mannitol, sorbitol, and microcrystalline cellulose for pharmaceutical applications; private family ownership enables decade-scale strategic investments without quarterly earnings pressure.
Weaknesses: €87M integration costs from the IFF acquisition contributed to a €265M net loss in 2025; European-centric manufacturing creates exposure to regional energy price volatility and logistics disruptions; limited presence in high-growth lipid nanoparticle and biologics excipient segments compared to Evonik and Croda.
Read More ▼
FranceEst. 193311,000+€4.9 billion (2025)40+ manufacturing sites and 20+ R&D centers globallyPrivate (family-owned)Score 89

Business Nature

Roquette operates as a privately-held, vertically integrated manufacturer of plant-based pharmaceutical excipients. The company controls its entire supply chain from agricultural raw materials corn, wheat, peas through to finished pharma-grade excipients.

Core Business Areas

Oral Solid Dosage Excipients — Core Business
• Mannitol, sorbitol, and xylitol for direct compression and wet granulation
• Microcrystalline cellulose MCC and starch-based binders/disintegrants
• Plant-based capsule materials for hard and soft gelatin alternatives

Injectable & Parenteral Excipients — Growth Segment
• High-purity polyols for injectable formulations
• Osmotic agents and stabilizers for biologic drug products

Nutrition & Health Ingredients — Adjacent Verticals
• Sugar-free coating systems for nutraceutical tablets
• Taste-masking and mouthfeel enhancers for oral liquid formulations

Industry Rankings

Corporate Report

Roquette is a France-based global leader in plant-based pharmaceutical excipients, headquartered in Lestrem. Founded in 1933, the privately-held company generated €4.9 billion in 2025 revenue with 11,000+ employees across 40+ manufacturing sites worldwide.

Business Overview

Roquette's pharmaceutical division focuses on oral solid dosage form excipients, including the world's broadest portfolio of polyols (mannitol, sorbitol, xylitol), microcrystalline cellulose, and modified starches. The transformative acquisition of IFF Pharma Solutions in 2025 cemented its position as the undisputed market leader in plant-based excipients. The company serves virtually every major pharmaceutical manufacturer globally.

Key Strengths

Full vertical integration from agricultural raw materials to finished pharma-grade excipients ensures unmatched supply security and cost competitiveness. The IFF acquisition created significant cross-selling opportunities. 20+ global R&D centers drive continuous innovation. Private ownership enables decade-scale strategic planning.

Challenges & Outlook

Integration of the IFF Pharma Solutions business will require 2-3 years to fully realize synergies. European-centric manufacturing exposes it to regional energy price volatility. Roquette earns a VerityRank Score of 89/100, reflecting its newly established market dominance.

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Lestrem, Hauts-de-France, France

Founded

1933

Employees

11,000+

Factories

40+ manufacturing sites and 20+ R&D centers globally

Categories

BiopharmaceuticalPharmaceutical Raw Materials & Excipients CompaniesPharmaceutical Raw Materials & Excipients ManufacturersSteel Raw Materials & Semi-Finished Products CompaniesSteel Raw Materials & Semi-Finished Products Manufacturers & SuppliersSteel Raw Materials & Semi-Finished Products IndustryNew Energy Systems IndustryTraditional Chinese Medicine & Health Products Brands

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website , Roquette 2025 Full-Year Results
Roquette Financial Information
Grand View Research — Excipients Market Analysis